Off-Label and Under the Radar: What the Evidence Says About Gabapentin for Anxiety

If your doctor has recommended gabapentin for anxiety, you may have done a quick search and found that the FDA has never formally approved it for that purpose. That can be unsettling. But off-label prescribing is both legal and common in the United States — and in the case of gabapentin, it has become one of the more frequently used strategies for patients who have not responded well to conventional anti-anxiety medications. The real question is not whether doctors prescribe it this way, but whether the evidence justifies it.

This article examines what the clinical literature says, why gabapentin has gained traction as an anxiolytic option, and how to recognize when it may not be the most appropriate path forward.

What Gabapentin Was Designed to Do

Gabapentin was originally developed as an anticonvulsant and received FDA approval in the 1990s for adjunctive treatment of partial seizures. It later gained approval for postherpetic neuralgia — the nerve pain that follows shingles — under the brand name Neurontin. A related formulation, Horizant, is approved for restless legs syndrome.

The drug works by binding to voltage-gated calcium channels in the central nervous system, which reduces the release of certain excitatory neurotransmitters. This calming effect on neural activity is what makes gabapentin pharmacologically interesting beyond its approved uses. It does not work on GABA receptors directly, despite what its name might imply, but the downstream result is a reduction in neuronal excitability — a mechanism that has relevance for anxiety as well as pain and seizures.

The Case for Gabapentin in Anxiety: What Studies Show

Research into gabapentin's anxiolytic properties has been ongoing since the late 1990s. Several randomized controlled trials and observational studies have examined its effects across different anxiety diagnoses, with mixed but occasionally promising results.

Generalized Anxiety Disorder (GAD): A small number of trials have found gabapentin to be modestly effective for GAD symptoms, particularly in reducing the physical manifestations of anxiety such as tension, restlessness, and sleep disruption. However, these studies tend to involve relatively small sample sizes, and the evidence has not been strong enough to prompt an FDA approval application.

Social Anxiety Disorder: This is arguably where gabapentin has shown the most consistent clinical support. A double-blind, placebo-controlled trial published in the Journal of Clinical Psychiatry found that gabapentin significantly reduced symptoms of social phobia compared to placebo. Some clinicians consider this one of the more compelling use cases for off-label prescribing.

Preoperative and Procedural Anxiety: Gabapentin has been studied as a preoperative anxiolytic with reasonably favorable results. Its ability to reduce anticipatory anxiety before surgical procedures is well-documented, and this is one area where its use is more broadly accepted in medical settings.

Panic Disorder and PTSD: Evidence here is considerably thinner. Some clinicians report anecdotal success, particularly for patients with comorbid pain conditions, but controlled trial data is limited.

Overall, the honest summary of the evidence is this: gabapentin shows real promise for certain anxiety presentations, but it has not been studied with the rigor or at the scale necessary to establish it as a first-line treatment.

Why Doctors Prescribe It Anyway

Despite the gaps in evidence, gabapentin has become a genuinely popular off-label choice among US prescribers. Several practical factors explain why.

First, traditional anti-anxiety medications carry their own significant limitations. Benzodiazepines — drugs like alprazolam and lorazepam — are effective but carry high risks of dependence and cognitive impairment. SSRIs and SNRIs, which are considered first-line treatments for most anxiety disorders, can take four to eight weeks to produce noticeable effects and frequently cause sexual side effects that lead patients to discontinue them. Buspirone is well-tolerated but not universally effective.

Gabapentin occupies a middle ground. It acts relatively quickly compared to antidepressants, does not carry the same dependence profile as benzodiazepines, and is generally well-tolerated. For patients who have cycled through multiple medications without success, it represents an option that operates through a different mechanism entirely.

Second, many anxiety patients have comorbid conditions — chronic pain, fibromyalgia, insomnia — for which gabapentin is also used. Prescribing one medication that addresses multiple symptoms simultaneously is a practical and appealing clinical strategy.

Risks and Limitations Worth Knowing

Gabapentin is not without drawbacks, and patients considering it for anxiety should weigh these carefully.

Sedation is the most commonly reported side effect and can be significant, particularly at higher doses. Dizziness, coordination problems, and cognitive dulling are also frequent complaints. For individuals whose anxiety already impairs daily functioning, adding a medication that blunts mental sharpness may create a different set of problems.

Physical dependence is possible with long-term use, and abrupt discontinuation can trigger withdrawal symptoms including heightened anxiety — a rebound effect that can be distressing and difficult to distinguish from the return of the original condition. This is particularly relevant for anxiety patients, since the fear of withdrawal can itself become a source of anxiety.

There is also a growing concern in the US about gabapentin misuse. Several states have added it to their prescription drug monitoring programs, and clinicians in addiction medicine have raised flags about its potential for abuse, especially among individuals with prior substance use disorders. Patients with that history should discuss this risk candidly with their provider before starting gabapentin.

When Other Treatments May Be More Appropriate

Gabapentin is not the right choice for every anxiety patient, and recognizing when to pursue alternatives is an important part of informed decision-making.

If you have not yet tried a first-line treatment — an SSRI or SNRI paired with cognitive behavioral therapy (CBT) — that is generally the more evidence-supported starting point. CBT in particular has decades of robust research behind it and produces durable results that medication alone does not always achieve.

Patients with a history of substance misuse should approach gabapentin cautiously and may be better served by non-pharmacological interventions or medications with a lower misuse potential.

Individuals whose anxiety is mild to moderate and situational may find that short-term therapeutic interventions, lifestyle modifications, or even structured mindfulness programs address their symptoms without the need for medication at all.

Finally, if anxiety is clearly secondary to an underlying medical condition — thyroid dysfunction, for example, or a sleep disorder — treating the root cause is nearly always more effective than layering on an anxiolytic.

Questions to Ask Your Doctor

If gabapentin has been proposed as part of your anxiety treatment, consider raising the following with your prescriber:

• What specific anxiety diagnosis is being targeted, and what does the evidence say for that indication?
• Have first-line treatments been tried and found ineffective or intolerable?
• What dose will be used, and how will effectiveness be evaluated?
• What is the plan if gabapentin needs to be discontinued?
• Are there any interactions with other medications or substances I am currently using?

These are not adversarial questions — they are the kind of informed inquiries that lead to better treatment outcomes.

The Bottom Line

Gabapentin can be a reasonable option for anxiety in specific clinical contexts, particularly for social anxiety disorder or for patients managing comorbid pain and anxiety simultaneously. The evidence is real but incomplete, and it should be understood as a tool within a broader treatment strategy rather than a definitive solution.

For most anxiety disorders, established treatments remain the stronger first choice. But medicine is rarely one-size-fits-all, and for some patients, gabapentin fills a gap that other medications have not. The key is making that decision with clear eyes — understanding both what the research supports and where the honest limits of the evidence lie.